


Figure 1A




Figure 1B




Figure 2



25
20
15
10
5
0
Tumor Size (mm)
Naive
Lm-LLO-E7
Lm-E7
Lm-Gag
Lm-LLO-NP
7
14
28
56
Days Post tumor Inoculation

Figure 3



Lm-LLO-E7
Lm-E7
Lm-LLO-NF
Lm-Gag
Naive
6000
5000
4000
3000
2000
1000
0
Δ cpm
1:20
1:40
1:80
1:160
Splenocyte:TC-1 ratio

Figure 4




Figure 5A




Figure 5B




Figure 6A




Figure 6B




Figure 6C




Figure 7A




Figure 7B




Figure 8A




Figure 8B




Figure 9A




Figure 9B

atggcgcgggatggtatactatacaagcgtatggttcaaaaagatactttgaattaagaagt
acaataaagttaacttcattagacaaaaagaaaaaacaaggaagaatagtacatagttataa
atacttggagagtgaggtgtaatatggggcagctgatttttgggtttcatatatgtagtt
tcaagattagccattgttgcggcagtagtttacttcttatacttattgagaaaaattgcaaa
taaatagaaaaaaagccttgtcaaacgaggctttttttatgcaaaaaatacgacgaatgaag
ccatgtgagacaatttggaatagcagacaacaaggaaggtagaacatgttttgaaaaattta
ctgattttcgattattattaacgcttgttaatttaaacatctcttatttttgctaacatata
agtatacaaagggacataaaaaggttaacagcgtttgttaaataggaagtatatgaaaatcc
*tcttttgtgtttctaaatttatttttaaggagtggaga***atgttgaaaaaaaataattggtta**
caaaatgcagtaatagcaatgctagtgttaattgtaggtctgtgcattaatatgggttctgg
aacaaaagtacaagctgagagtattcaacgaccaacgcctattaaccaagtttttccagatc
ccggcctagcgaatgcagtgaaacaaaatttagggaagcaaagtgttacagaccttgtatca
caaaaggaactatctggagtacaaaatttcaatggagataatagcaacattcaatctcttgc
gggaatgcaatttttcactaatttaaaagaacttcatctatcccataatcaaataagtgacc
ttagtcctttaaaggatctaactaagttagaagagctatctgtgaatagaaacagactgaaa
aatttaaacggaattccaagtgcttgtttatctcgcttgtttttagataacaacgaactcag
agatactgactcgcttattcatttgaaaaatctagaaatcttatctattcgtaataataagt
taaaaagtattgtgatgcttggtttttttatcaaaactagaggtattagatttgcatggtaat
gaaataacaaatacaggtggactaactagattgaagaaagttaactggatagatttaactgg
tcagaaatgtgtgaatgaaccagtaaaataccaaccagaattgtatataacaaatactgtca
aagacccagatggaagatggatatctccatattacatcagtaatggtgggagttatgtagat
ggttgtgtcctgtgggaattgccagtttatacagatgaagtaagctataagtttagcgaata
tataaacgttggggagactgaggctatatttgatggaacagttacacaacctatcaagaatt
aggacttgtgcacacctgtatactttgagctctcgtataatcacgagagctttttaaatatg
taagtcttaattatctcttgacaaaaagaacgtttattcgtataaggttaccaagagatgaa
gaaactatttttatttacaattcaccttgacaccaaaaactccatatgatatagtaaataagg
ttattaaacaagaaagaagaagcaacccgcttctcgcctcgttaacacgaacgttttcaggc
aaaaaattcaaactttcgtcgcgtagcttacgcgattttgaatgtgcgggattgctgaaaag
cagcccgttttttttatggcctccgaacgaatgagttagcaggccgcagatttgaacagctat
tttctatcttgttgtaacaaaattaagtggaggtggctcaccattagcaaagacatgttggt
aaacgatgggattcgtgcacgtgaagtaagattgatcgaccaagacggtgaacaattaggcg
tgaagagtaaaatcgatgcgcttcaaattgctgaaaaggctaatcttgatctagtgcttgtt
gctccaacagcgaaaccgccagtagctcgta

(SEQ ID NO: 74)

Figure 10

*GAATTC*atggcgcgggatggtatactatacaagcgtatggttcaaaaagatactttgaattaa
gaagtacaataaagttaacttcattagacaaaaagaaaaaacaaggaagaatagtacatagtt
ataaatacttggagagtgaggtgtaatatgggggcagctgatttttgggggtttcatatatgta
gtttcaagattagccattgttgcggcagtagtttacttcttatacttattgagaaaaattgca
aataaatagaaaaaaagccttgtcaaacgaggctttttttatgcaaaaaatacgacgaatgaa
gccatgtgagacaatttggaatagcagacaacaaggaaggtagaacatgttttgaaaaatttta
ctgattttcgattattattaacgcttgttaatttaaacatctcttatttttgctaacatataa
gtatacaaagggacataaaaaggttaacagcgtttgttaaataggaagtatatgaaaatcctc
ttttgtgtttctaaatttatttttaaggagtggaga*GGATCC*ggacttgtgcacacctgtata
ctttgagctctcgtataatcacgagagctttttaaatatgtaagtcttaattatctcttgaca
aaaagaacgtttattcgtataaggttaccaagagatgaagaaactattttatttacaattcac
cttgacaccaaaaactccatatgatatagtaaataaggttattaaacaagaaagaagaagcaa
cccgcttctcgcctcgttaacacgaacgttttcaggcaaaaaattcaaactttcgtcgcgtag
cttacgcgattttgaatgtgcgggattgctgaaaagcagcccgtttttttatggcctccgaac
gaatgagttagcaggccgcagatttgaacagctattttctatcttgttgtaacaaaattaagt
ggaggtggctcaccattagcaaagacatgttggtaaacgatgggattcgtgcacgtgaagtaa
gattgatcgaccaagacggtgaacaattaggcgtgaagagtaaaatcgatgcgcttcaaattg
ctgaaaaggctaatcttgatctagtgcttgttgctccaacagcgaaaccgccagtagctcgta
CTGCAG (SEQ ID NO: 75)

Figure 11



Lm-dd
prfA
plcA
hlyA
3
1
mpl
actA
plcB
2
4
Lm-ddΔactA
(N-T-19 aa and
C-T 28)
prfA
plcA
hlyA
3
1
mpl
plcB
2
4
3 2 1
3.0 Kb
1.2 Kb
1.0 kb
PCR using oligo's 1/2
1 2 3
3.4 Kb
1.6 Kb
1.0 kb
PCR using oligo's 3/4
Lanes
1: Control (Lm-dd)
2: Lm-dd ΔactA-colony no. 1
3 : Lm-dd ΔactA-colony no. 2

Figure 12

gcgccaaatcattggttgattggtgaggatgtctgtgtgcgtgggtcgcgagatgggcgaataagaagcattaaagatcctgacaaatat
aatcaagcggctcatatgaaagattacgaatcgcttccactcacagaggaaggcgactggggcggagttcattataatagtggtatccc
gaataaagcagcctataatactatcactaaacttggaaaagaaaaaacagaacagctttatttttcgcgccttaaagtactatttaacgaaaa
aatcccagtttaccgatgcgaaaaaagcgcttcaacaagcagcgaaagatttatatggtgaagatgcttctaaaaaagttgctgaagctt
gggaagcagttggggttaactgattaacaaatgttagagaaaaattaattctccaagtgatattcttaaaataattcatgaatatttttttcttata
ttagctaattaagaagataactaactgctaatccaatttttaacggaacaaattagtgaaaatgaaggccgaattttccttgttctaaaaaa
tgtattagcgtatcacgaggagggagtataa*gtgggattaaacagatttatgcgtgcgatgatggtggttttcattactgccaattgcaa*
*acgattaaccccgac**gtcgac**ccatacgacgttaattcttgcaatgttagctattggcgtgttctctttaggggcgtttatcaaaattatt*
*caattaagaaaaaataatta*aaaacacagaacgaaagaaaaagtgaggtgaatgatatgaaattcaaaaaggtggttctaggtatgtg
cttgatcgcaagtgttctagtctttccggtaacgataaaagcaaatgcctgttgtgatgaatacttacaaacacccgcagctccgcatgata
ttgacagcaaattaccacataaacttagttggtccgcggataacccgacaaatactgacgtaaatacgcactattggctttttaaacaagc
ggaaaaaatactagctaaagatgtaaatcatatgcgagctaatttaatgaatgaacttaaaaaattcgataaacaaatagctcaaggaata
tatgatgcggatcataaaaatccatattatgatactagtacatttttatctcatttttataatcctgatagagataatacttatttgccgggttttgc
taatgcgaaaataacaggagcaaagtatttcaatcaatcggtgactgattaccgagaagggaa (SEQ ID NO: 57)

Figure 13



DIAMETER/mm
20
15
10
5
0
7
14
21
28
35
52
62
DAYS
NAIVE
LMDD-TV3
LM-LLOE7

Figure 14




Figure 15A




Figure 15B




Figure 16A




Figure 16B




Figure 16C



Lm-control
Lm-LLO-ChHer2
ADXS31-164
*
Percentage tumor free mice
100
75
50
25
0
20
25
30
35
40
45
50
55
Weeks of age

Figure 17



Spleens
Gated on CD3+ T cells
0.3%
6.8%
68.4%
FOXP3
CD4
Non-treated
0.2%
6.1%
66.4%
LmddA control
0.3%
6.3%
67.0%
ADXS31-164
Gated on CD3+CD4+ T cells
0.9%
6.0%
3.0%
CD25
FOXP3
Non-treated
0.7%
5.9%
2.4%
LmddA control
0.6%
6.3%
2.2%
ADXS31-164

Figure 18




Figure 19A




Figure 19B




Figure 20A




Figure 20B



Figure 20C